Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)

Study:

A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab

Rationale:

n/a

Purpose:

This is a prospective pilot study to evaluate the usability and applicability of a self monitoring test of visual function with the handheld Health Management Tool (HMT) to remotely monitor neovascular Age Related Macular Degeneration (AMD) to detect a potential change in disease status.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Age Related Macular Degeneration (AMD) Device: Health Management Tool (HMT) Phase 4

Verified by Novartis Pharmaceuticals July, 2013

Sponsored by: Novartis Pharmaceuticals
Information provided by: Novartis
ClinicalTrials.gov identifier: NCT01542866

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: Open Label

Cleveland Clinic Cole/Eye Institute
Cleveland, Ohio 44915
United States

Novartis Pharmaceuticals., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site